The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital. They remain optimistic about the prospects for the sector in 2020 due to high levels of innovation and a relaxed regulatory environment, while a continuation in merger and acquisition (M&A) activity would also likely provide further support for biotech shares. The managers are very encouraged by the trust’s much-improved investment performance in recent months, noting they are being rewarde
24 Jan 2020
The Biotech Growth Trust - Positive outlook for 2020
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The Biotech Growth Trust - Positive outlook for 2020
Biotech Growth Trust PLC (BIOG:LON) | 955 257.9 2.9% | Mkt Cap: 319.8m
- Published:
24 Jan 2020 -
Author:
Mel Jenner -
Pages:
10
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital. They remain optimistic about the prospects for the sector in 2020 due to high levels of innovation and a relaxed regulatory environment, while a continuation in merger and acquisition (M&A) activity would also likely provide further support for biotech shares. The managers are very encouraged by the trust’s much-improved investment performance in recent months, noting they are being rewarde